Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 4/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 5/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | MASP2 | O00187 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708037 | 0.91 | AOC3 (0.51) | AOC3DAODHFRPLA2G7 | |
| Trifluoroacetic Acid SCHEMBL4245210 | 0.89 | AOC3 (0.44) | AOC3DAOBACE1DHFRPNP | |
| SCHEMBL11542383 | 0.85 | AOC3 (0.60) | AOC3PNPPLA2G7 | |
| SCHEMBL7716580 | 0.84 | DAO (0.50) | AOC3DAOPLA2G7 | |
| SCHEMBL7716692 | 0.81 | QTRT1 (0.52) | DAOPLA2G7 | |
| SCHEMBL7714577 | 0.81 | PLA2G7 (0.48) | DAOPLA2G7NPC1HTTRAB9A | |
| SCHEMBL224617 | 0.78 | AOC3 (0.73) | AOC3DAOBACE1MASP2RAB9A | |
| SCHEMBL10655643 | 0.77 | LMNA (0.60) | PLA2G7 | |
| SCHEMBL4211345 | 0.76 | TK1 (0.36) | AOC3PNP | |
| SCHEMBL8239236 | 0.76 | BACE1 (0.53) | DAOBACE1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1951680-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| US-6440965-B1 | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system | KRENITSKY PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | AOC3 1561/4885DAO 423/4885BACE1 9/4885 |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | AOC3 1561/4885DAO 423/4885BACE1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.